Home | Publications | Diseases | CNS place holder
place holder place holder

CNS

The CNS Market Outlook to 2010


Publication Date   May 2005
Publisher   Business Insights
Product Type   Report
Pages   188
ISBN Number   not applicable
Product Code   RBI029
Ask a question about this product?

Price £1,495.00

approximately: $2,220 | €1,759

Summary


CNS disorders contribute to as much as 35% of the disease burden in the seven major pharmaceutical markets (US, Japan, France, Germany, Italy, Spain and UK) as measured in terms of daily-adjusted life years. The worldwide patient population with CNS disorders is steadily rising, both in terms of prevalence and in terms of treatment, driven by an aging population, improving diagnostic techniques, increasing physician and patient awareness and a gradual shift away from the social stigma traditionally attached to many psychiatric conditions. The largest CNS indications in terms of prevalence are depression, migraine and pain, with 80m, 79m and 158m sufferers respectively across the seven major pharmaceutical markets. The fastest growing indication in terms of prevalence is Alzheimer's disease. By 2010 it is forecast that Alzheimer's disease will afflict 15m patients. In 2004 Parkinson's disease affected 2m patients across the seven markets, although epidemiological dynamics do not forecast this indication as a major growth area. Schizophrenia affected an estimated 8m patients in 2004, with prevalence forecast to rise to 9m patients by 2010. Growth rates associated with the prevalence of this disease are relatively robust compared to many other indications. Epilepsy is forecast to have relatively static growth in terms of prevalence of the disease, with 6m sufferers forecast to be affected by the disease by 2010.

Content


  • Executive Summary
    • Patient Potential
    • Global Market Analysis
    • Leading Players In The Cns Market
    • Analysis Of Potential Future Cns Blockbusters
  • Chapter 1 Patient Potential
    • Summary
    • Introduction
    • Alzheimer's Disease
    • Background
    • Prevalence
    • Forecast Prevalence
    • Depression
    • Background
    • Prevalence
    • Forecast Prevalence
    • Epilepsy
    • Background
    • Prevalence
    • Forecast Prevalence
    • Migraine
    • Background
    • Prevalence
    • Forecast Prevalence
    • Pain
    • Background
    • Neuropathic Lower Back Pain
    • Cancer Pain
    • Hiv Related Pain
    • Neuralgia/Fibromyalgia
    • Arthritic Pain
    • Post-Operative Pain
    • Diabetic Neuropathic Pain
    • Prevalence
    • Forecast Prevalence
    • Parkinson's Disease
    • Background
    • Prevalence
    • Forecast Prevalence
    • Schizophrenia
    • Background
    • Prevalence
    • Forecast Prevalence
  • Chapter 2 Global Market Analysis
    • Summary
    • Introduction
    • Alzheimer's Disease
    • Introduction
    • Analysis Of The Leading Alzheimer's Disease Treatments
    • Market Analysis By Drug Class
    • Cholinesterase Inhibitors
    • Nmda Antagonists
    • Depression
    • Introduction
    • Analysis Of The Leading Anti-Depressants
    • Market Analysis By Drug Class
    • Selective Serotonin Reuptake Inhibitors
    • Serotonin Norepinephrin Reuptake Inhibitors
    • Others
    • Epilepsy
    • Introduction
    • Analysis Of The Leading Epilepsy Treatments
    • Market Analysis By Drug Class
    • Traditional Anti-Convulsants
    • Second Generation Anti-Convulsants
    • Migraine
    • Introduction
    • Analysis Of The Leading Migraine Treatments
    • Market Analysis By Drug Class
    • Triptans
    • Pain
    • Introduction
    • Analysis Of The Leading Pain Treatments
    • Market Analysis By Drug Class
    • Narcotics
    • Non-Narcotics
    • Parkinson's Disease
    • Introduction
    • Analysis Of The Leading Parkinson's Disease Treatments
    • Market Analysis
    • Comt Inhibitors
    • Dopaminergics
    • Dopamine Agonists
    • Schizophrenia
    • Introduction
    • Analysis Of The Leading Anti-Psychotics
    • Market Analysis By Drug Class
    • Typical Anti-Psychotics
    • Atypical Anti-Psychotics
    • Cns Market Forecasts
  • Chapter 3 Leading Players In The Cns Market
    • Summary
    • Introduction
    • Global Market Shares
    • J&j
    • Marketed Products
    • R&d Compounds
    • Cns Portfolio Sales Forecasts
    • Pfizer
    • Marketed Products
    • R&d Compounds
    • Cns Portfolio Sales Forecasts
    • Gsk
    • Marketed Products
    • R&d Compounds
    • Cns Portfolio Sales Forecasts
    • Lilly
    • Marketed Products
    • R&d Compounds
    • Cns Portfolio Sales Forecasts
    • Sanofi-Aventis
    • Marketed Products
    • R&d Compounds
    • Cns Portfolio Sales Forecasts
    • Wyeth
    • Marketed Products
    • R&d Compounds
    • Cns Portfolio Sales Forecasts
    • Astrazeneca
    • Marketed Products
    • R&d Compounds
    • Cns Portfolio Sales Forecasts
    • Forest Labs
    • Marketed Products
    • R&d Compounds
    • Cns Portfolio Sales Forecasts
  • Chapter 4 Analysis Of Potential Future Cns Blockbusters
    • Summary
    • Introduction
    • Drug Profiles
    • Cymbalta (Duloxetine)
    • Lyrica (Pregabalin)
    • Symbyax (Olanzapine/Fluoxetine)
    • Indiplon
    • Transfenta (Fentanyl)
    • Dvs-233 (Desvenlafaxine)
    • Xaprila (Xaliproden)
    • Asenapine
    • Bifeprunox
    • Saredutant
    • Paliperidone
  • Chapter 5 Appendix
    • Ims Sales Figures
    • Glossary
    • Index
  • List Of Figures
    • Figure 1.1: Estimated Prevalence Of Pain By Indication In The Seven Major Pharmaceutical Markets, 2004
    • Figure 2.2: Competitive Dynamics In The Alzheimer's Disease Market, 2004
    • Figure 2.3: Competitive Dynamics Of Leading Brands In The Alzheimer's Disease Market, 2004
    • Figure 2.4: Competitive Dynamics In The Depression Market, 2004
    • Figure 2.5: Competitive Dynamics In The Depression Market, 2004
    • Figure 2.6: Competitive Dynamics In The Epilepsy Market, 2004
    • Figure 2.7: Competitive Dynamics Of Leading Brands In The Epilepsy Market, 2004
    • Figure 2.8: Competitive Dynamics Of Leading Brands In The Migraine Market, 2004
    • Figure 2.9: Competitive Dynamics In The Pain Market, 2004
    • Figure 2.10: Competitive Dynamics Of Leading Brands In The Pain Market, 2004
    • Figure 2.11: Competitive Dynamics Of Leading Brands In The Parkinson's Disease Market, 2004
    • Figure 2.12: Competitive Dynamics Of The Global Anti-Psychotics Market By Drug Class, 2003-04
    • Figure 2.13: Competitive Dynamics Of The Global Anti-Psychotics Market By Leading Brands, 2003-04
    • Figure 3.14: Key Players In The Global Cns Market, 2000 And 2004
    • Figure 4.15: Leading Drugs In Development, 2005
  • List Of Tables
    • Table 1.1: Estimated Prevalence Of Alzheimer's Disease In The 7 Major Markets, 2004
    • Table 1.2: Forecast Prevalence Of Alzheimer's Disease In The 7 Major Markets, 2005-10
    • Table 1.3: Estimated Prevalence Of Mdd In The 7 Major Markets, 2004
    • Table 1.4: Forecast Prevalence Of Mdd In The 7 Major Markets, 2005-10
    • Table 1.5: Estimated Prevalence Of Epilepsy In The 7 Major Markets, 2004
    • Table 1.6: Forecast Prevalence Of Epilepsy In The 7 Major Markets, 2005-10
    • Table 1.7: Estimated Prevalence Of Migraine In The 7 Major Markets, 2004
    • Table 1.8: Forecast Prevalence Of Migraine In The 7 Major Markets, 2005-10
    • Table 1.9: Estimated Prevalence Of Pain In The 7 Major Markets, 2004
    • Table 1.10: Forecast Prevalence Of Pain In The 7 Major Markets, 2005-10
    • Table 1.11: Estimated Prevalence Of Parkinson's Disease In The 7 Major Markets, 2004
    • Table 1.12: Forecast Prevalence Of Parkinson's Disease In The 7 Major Markets, 2005-10
    • Table 1.13: Estimated Prevalence Of Schizophrenia In The 7 Major Markets, 2004
    • Table 1.14: Forecast Prevalence Of Schizophrenia In The 7 Major Markets, 2005-10
    • Table 2.15: Breakdown Of The Global Alzheimer's Disease Market By Drug Class, 2003-04
    • Table 2.16: Breakdown Of The Global Alzheimer's Disease Market By Leading Brands, 2003-04
    • Table 2.17: Breakdown Of The Global Anti-Depressants And Mood Stabilizers Market By Drug Class, 2003-04
    • Table 2.18: Breakdown Of The Global Anti-Depressants Market By Leading Brands, 2003-04
    • Table 2.19: Breakdown Of The Global Epilepsy Market By Drug Class, 2003-04
    • Table 2.20: Breakdown Of The Global Epilepsy Market By Leading Brands, 2003-04
    • Table 2.21: Breakdown Of The Global Migraine Market By Drug Class, 2003-04
    • Table 2.22: Breakdown Of The Global Migraine Market By Leading Brands, 2003-04
    • Table 2.23: Breakdown Of The Global Pain Market By Drug Class, 2003-04
    • Table 2.24: Breakdown Of The Global Pain Market By Leading Brands, 2003-04
    • Table 2.25: Breakdown Of The Global Parkinson's Disease Market By Drug Class, 2003-04
    • Table 2.26: Breakdown Of The Global Parkinson's Disease Market By Leading Brands, 2003-04
    • Table 2.27: Breakdown Of The Global Anti-Psychotics Market By Drug Class, 2003-04
    • Table 2.28: Breakdown Of The Global Anti-Psychotics Market By Drug Class, 2003-04
    • Table 2.29: Forecast Global Sales For Major Cns Indications, 2004-10
    • Table 3.30: Key Players In The Global Cns Market, 2004
    • Table 3.31: J&j's Marketed Cns Portfolio, 2004
    • Table 3.32: J&j's Cns R&d Pipeline, 2005
    • Table 3.33: Forecast Sales For J&j's Cns Portfolio, 2004-10
    • Table 3.34: Pfizer's Marketed Cns Portfolio, 2004
    • Table 3.35: Pfizer's Cns R&d Pipeline, 2005
    • Table 3.36: Forecast Sales For Pfizer's Cns Portfolio, 2004-10
    • Table 3.37: Gsk's Marketed Cns Portfolio, 2004
    • Table 3.38: Gsk's Cns R&d Pipeline, 2005
    • Table 3.39: Forecast Sales For Gsk's Cns Portfolio, 2004-10
    • Table 3.40: Lilly's Marketed Cns Portfolio, 2004
    • Table 3.41: Lilly's Cns R&d Pipeline, 2005
    • Table 3.42: Forecast Sales For Lilly's Cns Portfolio, 2004-10
    • Table 3.43: Sanofi-Aventis' Marketed Cns Portfolio, 2004
    • Table 3.44: Sanofi-Aventis' Cns R&d Pipeline, 2004
    • Table 3.45: Forecast Sales For Sanofi-Aventis' Cns Portfolio, 2004-10
    • Table 3.46: Wyeth's Marketed Cns Portfolio, 2004
    • Table 3.47: Wyeth's Cns R&d Pipeline, 2004
    • Table 3.48: Forecast Sales For Wyeth's Cns Portfolio, 2004-10
    • Table 3.49: Astrazeneca's Marketed Cns Portfolio, 2004
    • Table 3.50: Astrazeneca's Cns R&d Pipeline, 2004
    • Table 3.51: Forecast Sales For Astrazeneca's Cns Portfolio, 2004-10
    • Table 3.52: Forest's Marketed Cns Portfolio, 2004
    • Table 3.53: Forest's Cns R&d Pipeline, 2004
    • Table 3.54: Forecast Sales For Forest's Cns Portfolio ($M), 2004-10